SV Health Investors is a specialist healthcare venture capital and growth equity firm founded in 1993, investing across biotechnology, medical devices, dementia, and healthcare technology. With offices in Boston and London, the firm creates and builds companies that advance science and transform healthcare across stages from early-stage to growth equity.
48% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (5 deals in the last 12 months vs 10 prior). Average disclosed round size is $62.4M (across 104 rounds with reported amounts).
Portfolio
71
Fund Size
—
Top Stage
Series B
Last 12 Mo
5
Team
Greg Madden
Managing Partner
Michael Balmuth
Managing Partner
Paul LaViolette
Managing Partner
Christian Jung
Partner
Laurence Barker
Partner
Luke Johnson
Operating Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 OMass Therapeutics | Series C | $310M | Oct 2026 |
 Draig Therapeutics | Series B | $65M | Jul 2026 |
 Mestag Therapeutics Limited | Series B | $40M | Mar 2026 |
| TTRexBio, Inc. | Series C | $50M | Jan 2026 |
 Health Payment Systems | Growth | $33M | Jan 2026 |
 Trex Bio | Unknown | $50M | Jan 2026 |
 PayMedix | Growth | $33M | Jan 2026 |
 Mestag Therapeutics | Seed | $95M | Jan 2026 |
 Mestag Therapeutics | Seed | $95M | Jan 2026 |
 Artios | Series D | $115M | Nov 2025 |
| DDualitas | Series A | $65M | Sep 2025 |
| DDualitas | Seed | — | Sep 2025 |
 Dualitas Therapeutics | Series A | $65M | Sep 2025 |
 NRG Therapeutics | Series B | $50M | Sep 2025 |
| Draig Therapeutics | Series A | $140M | Jun 2025 |
 Therini Bio | Series A | $39M | May 2025 |
 Imbria Pharmaceuticals | Series B | $57.5M | Apr 2025 |
| IImbria | Unknown | $57.5M | Apr 2025 |
| Draig Therapeutics | Series A | $140M | Jan 2025 |
 AdvanCell | Series C | $112M | Jan 2025 |
| IImbria | Series B | $57.5M | Jan 2025 |
| Dualitas Therapeutics | Series A | $65M | Jan 2025 |
| Imbria Pharmaceuticals | Series B | $59.2M | Jan 2025 |
 Enara Bio | Series B | $32.5M | Oct 2024 |
 LoQus23 | Series A | $43M | Oct 2024 |
Top Co-Investors
Last updated: 20 October 2026